Mount Sinai advances prostate care with AI-powered therapy designed to preserve continence and sexual function The Mount Sinai Hospital is ranked ...

Koelis, SAS ("Koelis" or the "Company", a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Prostate cancer is the second-leading cause of death among American men, killing one in 44. In the United States, 3.3 million men are survivors of prostate cancer, and the risk for developing the ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

Despite technologic advances and guideline recommendations, prostate MRI still lacks the accuracy to replace biopsies in active surveillance, data on almost 2,000 patients suggested. MRI had a 75% ...

Through GE Healthcare's AI Innovation Lab, Mass General Brigham and UW-Madison will pair the company's magnetic resonance imaging foundational model with real data from their hospital systems and then ...

Prostate cancer is the second-leading cause of cancer deaths in American men. Further, non-Hispanic Blacks have a higher incidence of prostate cancer and are more likely to die from it than are ...